Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

Sponsor
Glostrup University Hospital, Copenhagen
Study ID
NCT01029613
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    sc. inj. Humira 40 mg every other week from week 0 to 52

Study Details

Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with wholebody MRI etc.

Key Dates

Start date
Dec 31, 2009
Status verified
Aug 2015
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013

Study Design

Enrollment
40 participants (actual)

Arms

  • Arm: Rheumatoid arthritis

Primary Outcome Measure

EULAR response criteria [ Time Frame: 16 weeks ]

Related Studies